Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Myfortic (mycophenolic acid by Quarter
Myfortic (mycophenolic acid — prevention of organ transplant rejection) ($M)
Novartis Myfortic (mycophenolic acid: $110M in Q3 2026, up 13.4% from a year earlier.
Latest, Q3 2026
110
Period ended Sep 30, 2026
Change on a year earlier
+13.4%
97 in Q3 2025
History
6 quarters
Since Q1 2025
Sources
3
Documents cited below
Where the Q3 2026 figure comes from
“|| Myfortic 4 | 110 | 97 | 13 | 11”
Source: Novartis Form 6-K (0001114448-26-000014) ↗
Reported in Form 6-K & Form 20-F.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Myfortic (mycophenolic acid — prevention of organ transplant rejection) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 110 | +13.4% | Novartis Form 6-K (0001114448-26-000014) ↗ |
| Q2 2026 | Jun 30, 2026 | 105 | +2.9% | Novartis Form 6-K (0001114448-26-000012) ↗ |
| Q1 2026 | Mar 31, 2026 | 111 | +12.1% | Novartis Form 6-K (0001114448-26-000010) ↗ |
| Q3 2025 | Sep 30, 2025 | 97 | – | Novartis Form 6-K (0001114448-26-000014) ↗ |
| Q2 2025 | Jun 30, 2025 | 102 | – | Novartis Form 6-K (0001114448-26-000012) ↗ |
| Q1 2025 | Mar 31, 2025 | 99 | – | Novartis Form 6-K (0001114448-26-000010) ↗ |
Breakdown
What makes up myfortic (mycophenolic acid
Cite this data
StockData. (2026). Novartis Myfortic (mycophenolic acid ($M), quarterly Q1 2025–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-myfortic
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.